|drug3300||Surge capacity Wiki||1.00|
|drug2434||Patient Characteristics Wiki||1.00|
|drug1057||Differences in triage Wiki||1.00|
|D016739||Behavior, Addictive NIH||0.50|
|D019966||Substance-Related Disorders NIH||0.30|
There is one clinical trial.
This study will investigate how the case fatality in hospitalised patients with COVID-19 has changed throughout the pandemic. It will also explore possible mechanisms that could be driving these changes. This analysis will enhance our understanding of the virus, which will be important for researchers and clinicians to respond appropriately.
Description: The proportion of new admissions with COVID-19 who died over timeMeasure: Case fatality Time: 23 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports